Sample reports + format previews

What Delvant delivers at each tier

One full Tier 2 excerpt (ITP, ~25-30% of the deliverable). Plus format previews for Tier 1, Tier 3, and Tier 4 so you can see the shape of each scope before commissioning.

DLV-2026-002 - Tier 2 dossier - excerpt

TPO Receptor Agonists vs FcRn Inhibitors in Immune Thrombocytopenia

Mechanistic distinction, clinical signal comparison, and the off-treatment durability gap - 2L+ adult ITP

Hematology Medical Affairs / MSL Phase 2-3 RCT data Mechanism analysis

Tier 1 - Format preview

What a Tier 1 brief looks like

1 commissioned question. 10-15 page PDF + slide deck extract. 5 business days. From EUR 3,500. Example 6-slide deck (PDF) downloadable inside.

Tier 1 Competitive intel Slide deck PDF

Tier 3 - Format preview

What a Tier 3 quarterly retainer looks like

Rolling Tier 2 quality with change log. EUR 6-12K / month. Available Q4 2026 (T2 clients first). Example 6-slide deck (PDF) downloadable inside.

Tier 3 Quarterly cadence Slide deck PDF

Tier 4 - Format preview

What a Tier 4 consortium deliverable looks like

3-5 non-competing firms share fixed costs on a rolling cluster read. Member-specific addenda inside strict firewall. Onboarding 2027. Example 6-slide deck (PDF) downloadable inside.

Tier 4 Consortium Slide deck PDF

Sourcing standard. All published trial data citations point to ClinicalTrials.gov, the originating peer-reviewed publication, or the relevant EMA/FDA label. Mechanistic inference and editorial interpretation are explicitly tagged. Evidence tier system: RCT randomised controlled trial, RWE real-world evidence, Indirect cross-trial inference, Editorial analytical interpretation.

Anonymisation. No client names, no proprietary internal data, no commercial forecasts appear in public excerpts. Anchor numbers (e.g. RAISE 79%, ADVANCE IV 22%) are taken from the published RCTs they cite.